Continuous cultures of fused cells secreting antibody of predefined specificity, Nature, vol.256, issue.5517, pp.495-497, 1975. ,
Use of Radiolabeled Antibodies to Carcinoembryonic Antigen for the Detection and Localization of Diverse Cancers by External Photoscanning, New England Journal of Medicine, vol.298, issue.25, pp.1384-1388, 1978. ,
Treatment of a Patient with b Cell Lymphoma by 1-131 Lym-1 Monoclonal Antibodies, The International Journal of Biological Markers, vol.2, issue.1, pp.49-53, 1987. ,
Immunotherapy of Non-Hodgkin's Lymphomas, Hematology, vol.2001, issue.1, pp.221-240, 2001. ,
Radioimmunotherapy of non-Hodgkin lymphomas, Blood, vol.101, issue.2, pp.391-398, 2003. ,
Recent progress in cancer therapy with radiolabeled monoclonal antibodies, Therapeutic Delivery, vol.2, issue.6, pp.675-679, 2011. ,
Clinical radioimmunotherapy?the role of radiobiology, Nature Reviews Clinical Oncology, vol.8, issue.12, pp.720-734, 2011. ,
URL : https://hal.archives-ouvertes.fr/hal-02962928
Review of radiation-induced bystander effects, Human & Experimental Toxicology, vol.23, issue.2, pp.87-89, 2004. ,
The unique physiology of solid tumors: opportunities (and problems) for cancer therapy, Cancer Res, vol.58, issue.7, pp.1408-1424, 1998. ,
3D microvascular architecture of pre-cancerous lesions and invasive carcinomas of the colon, British Journal of Cancer, vol.84, issue.10, pp.1354-1362, 2001. ,
Enhancement of fluid filtration across tumor vessels: Implication for delivery of macromolecules, Proceedings of the National Academy of Sciences, vol.96, issue.6, pp.3137-3142, 1999. ,
Biodistribution Mechanisms of Therapeutic Monoclonal Antibodies in Health and Disease, The AAPS Journal, vol.12, issue.1, pp.33-43, 2009. ,
Antibody tumor penetration: Transport opposed by systemic and antigen-mediated clearance, Advanced Drug Delivery Reviews, vol.60, issue.12, pp.1421-1434, 2008. ,
A comparative autoradiographic study demonstrating differential intratumor localization of monoclonal antibodies to cell surface (Lym-1) and intracellular (TNT-1) antigens, J Nucl Med, vol.31, issue.6, pp.1059-66, 1990. ,
Different ways to improve the clinical effectiveness of radioimmunotherapy in solid tumors, Journal of Cancer Research and Therapeutics, vol.5, issue.9, p.36, 2009. ,
Rituximab and its role as maintenance therapy in non-Hodgkin lymphoma, Expert Review of Anticancer Therapy, vol.7, issue.3, pp.257-273, 2007. ,
Glomerular Filtration Rate After Alpha-Radioimmunotherapy with 211At-MX35-F(ab?)2: A Long-Term Study of Renal Function in Nude Mice, Cancer Biotherapy and Radiopharmaceuticals, vol.24, issue.6, pp.649-658, 2009. ,
Intraperitoneal -Particle Radioimmunotherapy of Ovarian Cancer Patients: Pharmacokinetics and Dosimetry of 211At-MX35 F(ab')2--A Phase I Study, Journal of Nuclear Medicine, vol.50, issue.7, pp.1153-1160, 2009. ,
Development and preclinical studies of 64Cu-NOTA-pertuzumab F(ab?)2 for imaging changes in tumor HER2 expression associated with response to trastuzumab by PET/CT, mAbs, vol.9, issue.1, pp.154-164, 2016. ,
Gallium-68-Labeled Anti-HER2 Single-Chain Fv Fragment: Development and In Vivo Monitoring of HER2 Expression, Molecular Imaging and Biology, vol.17, issue.1, pp.102-110, 2014. ,
, Imaging of Early Response to Predict Prognosis in the First-Line Management of Follicular Non-Hodgkin Lymphoma with Iodine-131-Rituximab Radioimmunotherapy, Diagnostics, vol.7, issue.2, p.26, 2017.
Continued Excellent Outcomes in Previously Untreated Patients With Follicular Lymphoma After Treatment With CHOP Plus Rituximab or CHOP Plus 131I-Tositumomab: Long-Term Follow-Up of Phase III Randomized Study SWOG-S0016, Journal of Clinical Oncology, vol.36, issue.7, pp.697-703, 2018. ,
Radioimmunotherapy for non-Hodgkin's lymphoma: positioning, safety, and efficacy of 90Y-ibritumomab. 10 years of experience and follow-up, Revista Española de Medicina Nuclear e Imagen Molecular (English Edition), vol.36, issue.1, pp.13-19, 2017. ,
Radioimmunotherapy for non-Hodgkin's lymphoma: positioning, safety, and efficacy of 90Y-ibritumomab. 10 years of experience and follow-up, Revista Española de Medicina Nuclear e Imagen Molecular (English Edition), vol.36, issue.1, pp.13-19, 2017. ,
Phase I/II Trial of Anticarcinoembryonic Antigen Radioimmunotherapy, Gemcitabine, and Hepatic Arterial Infusion of Fluorodeoxyuridine Postresection of Liver Metastasis for Colorectal Carcinoma, Cancer Biotherapy and Radiopharmaceuticals, vol.32, issue.7, pp.258-265, 2017. ,
Radioimmunotherapy of Metastatic Prostate Cancer with <sup>177</sup>Lu-DOTAhuJ591 Anti Prostate Specific Membrane Antigen Specific Monoclonal Antibody, Current Radiopharmaceuticals, vol.9, issue.1, pp.44-53, 2015. ,
Targeting, toxicity, and efficacy of 2-step, pretargeted radioimmunotherapy using a chimeric bispecific antibody and 131I-labeled bivalent hapten in a phase I optimization clinical trial, J Nucl Med, vol.47, issue.2, pp.247-55, 2006. ,
MP50-19 DOSE-FRACTIONATED ANTI-PSMA RADIOIMMUNOTHERAPY ( 177 LU-J591) FOR MCRPC, Journal of Urology, vol.195, issue.4S, p.680, 2016. ,
Peptide Receptor Radionuclide Therapy: Preclinical Findings, Radionuclide Peptide Cancer Therapy, vol.44, pp.127-143, 2016. ,
Relationships between tumor size and curability for uniformly targeted therapy with beta-emitting radionuclides, J Nucl Med, vol.36, issue.10, pp.1902-1911, 1995. ,
Clinical Experience with -Particle Emitting 211At: Treatment of Recurrent Brain Tumor Patients with 211At-Labeled Chimeric Antitenascin Monoclonal Antibody 81C6, Journal of Nuclear Medicine, vol.49, issue.1, pp.30-38, 2007. ,
Development of Lu-177-trastuzumab for radioimmunotherapy of HER2 expressing breast cancer and its feasibility assessment in breast cancer patients, International Journal of Cancer, vol.140, issue.4, pp.938-947, 2016. ,
Synthesis and Preclinical Evaluation of 177Lu-CHX-A?-DTPA-Rituximab as a Radioimmunotherapeutic Agent for Non-Hodgkin's Lymphoma, Cancer Biotherapy and Radiopharmaceuticals, vol.30, issue.6, pp.240-246, 2015. ,
Radiolabeling of antibodies, Cancer Res, vol.40, issue.8, pp.3036-3078, 1980. ,
The labelling of proteins to high specific radioactivities by conjugation to a 125I-containing acylating agent. Application to the radioimmunoassay, Biochemical Journal, vol.133, issue.3, pp.529-538, 1973. ,
Preparation and in vivo evaluation of linkers for 211 At labeling of humanized anti-Tac, Nuclear Medicine and Biology, vol.28, issue.7, pp.845-856, 2001. ,
Bifunctional coupling agents for radiolabeling of biomolecules and target-specific delivery of metallic radionuclides, Advanced Drug Delivery Reviews, vol.60, issue.12, pp.1347-1370, 2008. ,
A One-Pot Three-Component Double-Click Method for Synthesis of [67Cu]-Labeled Biomolecular Radiotherapeutics, Scientific Reports, vol.7, issue.1, pp.1912-1921, 2017. ,
Radiolabeling of HTE1PA: A new monopicolinate cyclam derivative for Cu-64 phenotypic imaging. In vitro and in vivo stability studies in mice, Nuclear Medicine and Biology, vol.41, pp.e49-e57, 2014. ,
URL : https://hal.archives-ouvertes.fr/hal-01529578
Assessment of treatment-related myelodysplastic syndromes and acute myeloid leukemia in patients with non-Hodgkin lymphoma treated with tositumomab and iodine I131 tositumomab, Blood, vol.105, issue.12, pp.4576-4582, 2005. ,
Efficacy and Safety of Tositumomab and Iodine-131 Tositumomab (Bexxar) in B-Cell Lymphoma, Progressive After Rituximab, Journal of Clinical Oncology, vol.23, issue.4, pp.712-719, 2005. ,
Radioimmunotherapy Confers Long-Term Survival to Lymphoma Patients with Acceptable Toxicity: Registry Analysis by the International Radioimmunotherapy Network, Journal of Nuclear Medicine, vol.52, issue.9, pp.1354-1360, 2011. ,
Treatment-Related Myelodysplastic Syndrome and Acute Myelogenous Leukemia in Patients Treated With Ibritumomab Tiuxetan Radioimmunotherapy, Journal of Clinical Oncology, vol.25, issue.27, pp.4285-4292, 2007. ,
Tositumomab and Iodine-131 Tositumomab Produces Durable Complete Remissions in a Subset of Heavily Pretreated Patients With Low-Grade and Transformed Non-Hodgkin?s Lymphomas, Journal of Clinical Oncology, vol.23, issue.30, pp.7565-7573, 2005. ,
A randomized study comparing yttrium-90 ibritumomab tiuxetan (Zevalin) and high-dose BEAM chemotherapy versus BEAM alone as the conditioning regimen before autologous stem cell transplantation in patients with aggressive lymphoma, Cancer, vol.118, issue.19, pp.4706-4714, 2012. ,
Phase III Trial of Consolidation Therapy With Yttrium-90?Ibritumomab Tiuxetan Compared With No Additional Therapy After First Remission in Advanced Follicular Lymphoma, Journal of Clinical Oncology, vol.26, issue.32, pp.5156-5164, 2008. ,
Abbreviated Chemotherapy With Fludarabine Followed by Tositumomab and Iodine I 131 Tositumomab for Untreated Follicular Lymphoma, Journal of Clinical Oncology, vol.23, issue.24, pp.5696-5704, 2005. ,
Rituximab plus Short-Duration Chemotherapy Followed by Yttrium-90 Ibritumomab Tiuxetan as First-Line Treatment for Patients with Follicular Non-Hodgkin Lymphoma: A Phase II Trial of the Sarah Cannon Oncology Research Consortium, Clinical Lymphoma and Myeloma, vol.9, issue.3, pp.223-228, 2009. ,
Rituximab plus Short-Duration Chemotherapy Followed by Yttrium-90 Ibritumomab Tiuxetan as First-Line Treatment for Patients with Follicular Non-Hodgkin Lymphoma: A Phase II Trial of the Sarah Cannon Oncology Research Consortium, Clinical Lymphoma and Myeloma, vol.9, issue.3, pp.223-228, 2009. ,
Phase II Trial of Short-Course R-Chop Followed by 90Y-Ibritumomab Tiuxetan in Previously Untreated High-Risk Elderly Diffuse Large B-Cell Lymphoma Patients, Clinical Cancer Research, vol.16, issue.15, pp.3998-4004, 2010. ,
Radioimmunotherapy for first-line and relapse treatment of aggressive B-cell non-Hodgkin lymphoma: an analysis of 215 patients registered in the international RIT-Network, European Journal of Nuclear Medicine and Molecular Imaging, vol.41, issue.8, pp.1585-1592, 2014. ,
90Yttrium-Ibritumomab-Tiuxetan as First-Line Treatment for Follicular Lymphoma: 30 Months of Follow-Up Data From an International Multicenter Phase II Clinical Trial, Journal of Clinical Oncology, vol.31, issue.3, pp.308-313, 2013. ,
90 Y-ibritumomab tiuxetan: a nearly forgotten opportunity, Oncotarget, vol.7, issue.7, pp.7597-7609, 2015. ,
Radioimmunotherapy of Lymphoma: A Treatment Approach Ahead of Its Time or Past Its Sell-By Date?, Journal of Clinical Oncology, vol.28, issue.18, pp.2944-2946, 2010. ,
Radioimmunotherapy of non-Hodgkin' lymphoma with 90Y-DOTA humanized anti-CD22 IgG (90Y-Epratuzumab): do tumor targeting and dosimetry predict therapeutic response?, J Nucl Med, vol.44, issue.12, pp.2000-2018, 2003. ,
Dose-fractionated radioimmunotherapy in non-Hodgkin's lymphoma using DOTA-conjugated, 90Y-radiolabeled, humanized anti-CD22 monoclonal antibody, epratuzumab, Clin Cancer Res, vol.11, issue.14, pp.5215-5237, 2005. ,
Evaluation of response to fractionated radioimmunotherapy with 90Y-epratuzumab in non-Hodgkin's lymphoma by 18F-fluorodeoxyglucose positron emission tomography, Haematologica, vol.93, issue.3, pp.390-397, 2008. ,
High Rates of Durable Responses With Anti-CD22 Fractionated Radioimmunotherapy: Results of a Multicenter, Phase I/II Study in Non-Hodgkin's Lymphoma, Journal of Clinical Oncology, vol.28, issue.23, pp.3709-3716, 2010. ,
A re-examination of radioimmunotherapy in the treatment of non-Hodgkin lymphoma: prospects for dual-targeted antibody/radioantibody therapy, Blood, vol.113, issue.17, pp.3891-3895, 2009. ,
Pretargeted versus directly targeted radioimmunotherapy combined with anti-CD20 antibody consolidation therapy of non-Hodgkin lymphoma, J Nucl Med, vol.50, issue.3, pp.444-53, 2009. ,
Therapy of Advanced B-Lymphoma Xenografts with a Combination of 90Y-anti-CD22 IgG (Epratuzumab) and Unlabeled Anti-CD20 IgG (Veltuzumab), Clinical Cancer Research, vol.14, issue.19, pp.6154-6160, 2008. ,
Multiple myeloma, N Engl J Med, vol.351, issue.18, pp.1860-73, 2004. ,
URL : https://hal.archives-ouvertes.fr/hal-00557757
Multiple myeloma, N Engl J Med, vol.364, issue.11, pp.1046-60, 2011. ,
URL : https://hal.archives-ouvertes.fr/hal-01282339
Treatment Options for Relapsed and Refractory Multiple Myeloma, Clinical Cancer Research, vol.17, issue.6, pp.1264-1277, 2011. ,
Anti-CD20 monoclonal antibody therapy in multiple myeloma, Br J Haematol, vol.141, issue.2, pp.135-183, 2008. ,
Preliminary studies for an immunotherapeutic approach to the treatment of human myeloma using chimeric anti-CD38 antibody, Blood, vol.77, issue.5, pp.1071-1079, 1991. ,
Anti-CD54 (ICAM-1) has antitumor activity in SCID mice with human myeloma cells, Cancer Res, vol.55, issue.3, pp.610-616, 1995. ,
Combining milatuzumab with bortezomib, doxorubicin, or dexamethasone improves responses in multiple myeloma cell lines, Clin Cancer Res, vol.15, issue.8, pp.2808-2825, 2009. ,
A novel membrane antigen selectively expressed on terminally differentiated human B cells, Blood, vol.84, issue.6, pp.1922-1930, 1994. ,
Humanized anti-HM1.24 antibody mediates myeloma cell cytotoxicity that is enhanced by cytokine stimulation of effector cells, Blood, vol.93, issue.11, pp.3922-3952, 1999. ,
Combinatorial efficacy of anti-CS1 monoclonal antibody elotuzumab (HuLuc63) and bortezomib against multiple myeloma, Mol Cancer Ther, vol.8, issue.9, pp.2616-2640, 2009. ,
Biologic effects of anti-interleukin-6 murine monoclonal antibody in advanced multiple myeloma, Blood, vol.86, issue.2, pp.685-691, 1995. ,
Murine anti-interleukin-6 monoclonal antibody therapy for a patient with plasma cell leukemia, Blood, vol.78, issue.5, pp.1198-204, 1991. ,
CD66a (CEACAM1) is the only CD66 variant expressed on the surface of plasma cells in multiple myeloma: a refined target for radiotherapy trials?, British Journal of Haematology, vol.149, issue.5, pp.795-796, 2010. ,
Radioimmunotherapy with radretumab in patients with relapsed hematologic malignancies, J Nucl Med, vol.53, issue.6, pp.922-929, 2012. ,
Dosimetry results suggest feasibility of radioimmunotherapy using anti-CD138 (B-B4) antibody in multiple myeloma patients, Tumour Biol, vol.33, issue.3, pp.679-88, 2012. ,
Single-dose anti-CD138 radioimmunotherapy: bismuth-213 is more efficient than lutetium-177 for treatment of multiple myeloma in a preclinical model, Front Med, vol.2, issue.12, p.76, 2015. ,
URL : https://hal.archives-ouvertes.fr/inserm-01817464
CD38-bispecific antibody pretargeted radioimmunotherapy for multiple myeloma and other B-cell malignancies, Blood, vol.131, issue.6, pp.611-620, 2018. ,
Syndecan-1: a dynamic regulator of the myeloma microenvironment, Clinical & Experimental Metastasis, vol.25, issue.2, pp.149-159, 2007. ,
A plasmocyte selective monoclonal antibody (B-B4) recognizes syndecan-1, British Journal of Haematology, vol.94, issue.2, pp.318-323, 1996. ,
Cell surface proteoglycan syndecan-1 mediates hepatocyte growth factor binding and promotes Met signaling in multiple myeloma, Blood, vol.99, issue.4, pp.1405-1410, 2002. ,
Comparison of the biologic effects of MA5 and B-B4 monoclonal antibody labeled with iodine-131 and bismuth-213 on multiple myeloma, Cancer, vol.94, issue.S4, pp.1202-1209, 2002. ,
Validation of 213Bi-alpha radioimmunotherapy for multiple myeloma, Clin Cancer Res, vol.5, pp.3165-70, 1999. ,
European cancer mortality predictions for the year 2013, Annals of Oncology, vol.24, issue.3, pp.792-800, 2013. ,
Secondary Hormonal Therapy for Advanced Prostate Cancer, The Journal of Urology, vol.175, issue.1, p.27???34, 2006. ,
Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer, New England Journal of Medicine, vol.351, issue.15, pp.1502-1512, 2004. ,
Docetaxel and Estramustine Compared with Mitoxantrone and Prednisone for Advanced Refractory Prostate Cancer, New England Journal of Medicine, vol.351, issue.15, pp.1513-1520, 2004. ,
Radionuclide therapy and integrated protocols for bone metastases, Q J Nucl Med Mol Imaging, vol.55, issue.4, pp.431-478, 2011. ,
Anti-prostate-Specific membrane antigen-based radioimmunotherapy for prostate cancer, Cancer, vol.116, issue.S4, pp.1075-1083, 2010. ,
Combined modality radioimmunotherapy for human prostate cancer xenografts with taxanes and90yttrium-DOTA-peptide-ChL6, The Prostate, vol.50, issue.1, pp.27-37, 2001. ,
High-Dose Radioimmunotherapy Combined with Fixed, Low-Dose Paclitaxel in Metastatic Prostate and Breast Cancer by Using a MUC-1 Monoclonal Antibody, m170, Linked to Indium-111/Yttrium-90 via a Cathepsin Cleavable Linker with Cyclosporine to Prevent Human Anti-mouse Antibody, Clinical Cancer Research, vol.11, issue.16, pp.5920-5927, 2005. ,
Radioimmunotherapy for metastatic prostate cancer using a high affinity antibody, International Journal of Radiation Oncology*Biology*Physics, vol.27, issue.6, p.318, 1993. ,
A dual-monoclonal sandwich assay for prostate-specific membrane antigen: Levels in tissues, seminal fluid and urine, The Prostate, vol.43, issue.2, pp.150-157, 2000. ,
Expression of prostate-specific membrane antigen in normal, benign, and malignant prostate tissues, Urologic Oncology: Seminars and Original Investigations, vol.1, issue.1, pp.18-28, 1995. ,
Expression of the prostate-specific membrane antigen, Cancer Res, vol.54, issue.7, pp.1807-1818, 1994. ,
Molecular cloning of a complementary DNA encoding a prostate-specific membrane antigen, Cancer Res, vol.53, issue.2, pp.227-257, 1993. ,
5162504 Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients, Biotechnology Advances, vol.11, issue.2, p.352, 1993. ,
Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma, Cancer, vol.82, issue.11, pp.2256-2261, 1998. ,
Development of 5D3-DM1: A Novel Anti-Prostate-Specific Membrane Antigen Antibody-Drug Conjugate for PSMA-Positive Prostate Cancer Therapy, Cancer Res, vol.58, issue.18, pp.4055-60 ,
Monoclonal antibodies to the extracellular domain of prostate-specific membrane antigen also react with tumor vascular endothelium, Cancer Res, vol.57, issue.17, pp.3629-3663, 1997. ,
Phase I Trial of Yttrium-90?Labeled Anti?Prostate-Specific Membrane Antigen Monoclonal Antibody J591 for Androgen-Independent Prostate Cancer, Journal of Clinical Oncology, vol.22, issue.13, pp.2522-2531, 2004. ,
Phase I Trial of 177Lutetium-Labeled J591, a Monoclonal Antibody to Prostate-Specific Membrane Antigen, in Patients With Androgen-Independent Prostate Cancer, Journal of Clinical Oncology, vol.23, issue.21, pp.4591-4601, 2005. ,
Therapeutic Radionuclides: Biophysical and Radiobiologic Principles, Seminars in Nuclear Medicine, vol.38, issue.5, pp.358-366, 2008. ,
Radiobiology of ? Particles. IV. Cell Inactivation by ? Particles of Energies 0.4-3.5 MeV, Radiation Research, vol.133, issue.3, p.289, 1993. ,
MIRD Pamphlet No. 22 (abridged): radiobiology and dosimetry of alphaparticle emitters for targeted radionuclide therapy, J Nucl Med, vol.51, issue.2, pp.311-339, 2010. ,
?-Particle-emitting radioisotopes coupled to antibody for acute myeloid leukaemia treatment, Molecular Medicine Today, vol.3, issue.6, pp.232-233, 1997. ,
Targeted alpha therapy using a novel CD70 targeted thorium-227 conjugate in in vitro and in vivo models of renal cell carcinoma, Oncotarget, vol.8, issue.34, pp.56311-56326, 2017. ,
Targeting Melanoma with 211 At/131I-Methylene Blue: Preclinical and Clinical Experience, Hybridoma, vol.18, issue.1, pp.77-82, 1999. ,
Absorbed Doses and Risk Estimates of 211At-MX35 F(ab')2 in Intraperitoneal Therapy of Ovarian Cancer Patients, International Journal of Radiation Oncology*Biology*Physics, vol.93, issue.3, pp.569-576, 2015. ,
EANM guideline for radionuclide therapy with radium-223 of metastatic castration-resistant prostate cancer, European Journal of Nuclear Medicine and Molecular Imaging, vol.45, issue.5, pp.824-845, 2017. ,
Treatment of Metastatic Bone Disease and the Emerging Role of Radium-223, Seminars in Nuclear Medicine, vol.46, issue.2, pp.99-104, 2016. ,
Radium-223 dichloride therapy in breast cancer with osseous metastases, BMJ Case Reports, vol.2015, issue.nov17 2, pp.bcr2015211152-bcr2015211152, 2015. ,
Current status and perspectives in alpha radioimmunotherapy, Q J Nucl Med Mol Imaging, vol.50, issue.4, pp.322-331, 2006. ,
Cyclotron production of Ac-225 for targeted alpha therapy11Dedicated to Prof. Dr. Franz Baumgärtner on the occasion of his 75th birthday., Applied Radiation and Isotopes, vol.62, issue.3, pp.383-387, 2005. ,
The ARRONAX Project, Current Radiopharmaceuticalse, vol.4, issue.3, pp.186-196, 2011. ,
A nephron-based model of the kidneys for macro-to-micro ?-particle dosimetry, Physics in Medicine and Biology, vol.57, issue.13, pp.4403-4424, 2012. ,
A bone marrow toxicity model for223Ra alpha-emitter radiopharmaceutical therapy, Physics in Medicine and Biology, vol.57, issue.10, pp.3207-3222, 2012. ,
Medullary thyroid carcinoma, Cancer, vol.88, issue.5, pp.1139-1148, 2000. ,
Prognostic Significance of SomaticRETOncogene Mutations in Sporadic Medullary Thyroid Cancer: A 10-Year Follow-Up Study, The Journal of Clinical Endocrinology & Metabolism, vol.93, issue.3, pp.682-687, 2008. ,
The Ki67 index a prognostic marker in medullary thyroid carcinoma, British Journal of Cancer, vol.89, issue.11, pp.2093-2097, 2003. ,
Expression of cdc25B and cdc25A in medullary thyroid carcinoma: cdc25B expression level predicts a poor prognosis, Cancer Letters, vol.229, issue.2, pp.291-297, 2005. ,
Long-term Outcome of Reoperations for Medullary Thyroid Carcinoma, World Journal of Surgery, vol.32, issue.5, pp.754-765, 2008. ,
Prognostic Impact of Serum Calcitonin and Carcinoembryonic Antigen Doubling-Times in Patients with Medullary Thyroid Carcinoma, The Journal of Clinical Endocrinology & Metabolism, vol.90, issue.11, pp.6077-6084, 2005. ,
Progression of medullary thyroid carcinoma: assessment with calcitonin and carcinoembryonic antigen doubling times, Eur J Endocrinol, vol.158, issue.2, pp.239-285, 2008. ,
A Phase II Trial of Imatinib Therapy for Metastatic Medullary Thyroid Carcinoma, The Journal of Clinical Endocrinology & Metabolism, vol.92, issue.9, pp.3466-3469, 2007. ,
Efficacy of imatinib mesylate in advanced medullary thyroid carcinoma, European Journal of Endocrinology, vol.157, issue.2, pp.215-220, 2007. ,
Phase II Clinical Trial of Sorafenib in Metastatic Medullary Thyroid Cancer, Journal of Clinical Oncology, vol.28, issue.14, pp.2323-2330, 2010. ,
Phase II Study of Safety and Efficacy of Motesanib in Patients With Progressive or Symptomatic, Advanced or Metastatic Medullary Thyroid Cancer, Journal of Clinical Oncology, vol.27, issue.23, pp.3794-3801, 2009. ,
Vandetanib for the Treatment of Patients With Locally Advanced or Metastatic Hereditary Medullary Thyroid Cancer, Journal of Clinical Oncology, vol.28, issue.5, pp.767-772, 2010. ,
Vandetanib (VAN) in locally advanced or metastatic medullary thyroid cancer (MTC): A randomized, double-blind phase III trial (ZETA)., Journal of Clinical Oncology, vol.28, issue.15_suppl, pp.5503-5503, 2010. ,
Phase I/II trial of131I-MN-14 F(ab)2 anti-carcinoembryonic antigen monoclonal antibody in the treatment of patients with metastatic medullary thyroid carcinoma, Cancer, vol.85, issue.8, pp.1828-1842, 1999. ,
Phase I/II trial of131I-MN-14 F(ab)2 anti-carcinoembryonic antigen monoclonal antibody in the treatment of patients with metastatic medullary thyroid carcinoma, Cancer, vol.85, issue.8, pp.1828-1842, 1999. ,
Perspectives on cancer therapy with radiolabeled monoclonal antibodies, J Nucl Med, vol.46, issue.1, pp.115-142, 2005. ,
Targeting of melanoma cells via biospecific antibodies (Bs-MAbs), Melanoma Research, vol.3, issue.1, p.19, 1993. ,
Radiolabeled Antibodies for Cancer Imaging and Therapy, Antibody Engineering, vol.907, pp.681-697, 2012. ,
Antibody Pretargeting Advances Cancer Radioimmunodetection and Radioimmunotherapy, Journal of Clinical Oncology, vol.24, issue.5, pp.823-834, 2006. ,
Pretargeting with the Affinity Enhancement System for Radioimmunotherapy, Cancer Biotherapy and Radiopharmaceuticals, vol.14, issue.3, pp.153-166, 1999. ,
Retraction: ?Radioimmunotherapy of small-volume disease of metastatic colorectal cancer: Results of a phase II trial with the iodine-131-labeled humanized anti-carcinoembryonic antigen antibody hMN-14,?, Cancer, vol.121, issue.13, pp.2290-2290, 2015. ,
Bispecific antibody and bivalent hapten radioimmunotherapy in CEA-producing medullary thyroid cancer xenograft, J Nucl Med, vol.40, issue.1, pp.198-204, 1999. ,
Survival Improvement in Patients With Medullary Thyroid Carcinoma Who Undergo Pretargeted Anti?Carcinoembryonic-Antigen Radioimmunotherapy: A Collaborative Study With the French Endocrine Tumor Group, Journal of Clinical Oncology, vol.24, issue.11, pp.1705-1711, 2006. ,
Phase II Trial of Anticarcinoembryonic Antigen Pretargeted Radioimmunotherapy in Progressive Metastatic Medullary Thyroid Carcinoma: Biomarker Response and Survival Improvement, Journal of Nuclear Medicine, vol.53, issue.8, pp.1185-1192, 2012. ,
URL : https://hal.archives-ouvertes.fr/hal-00932253
Multifunctional Antibodies by the Dock-and-Lock Method for Improved Cancer Imaging and Therapy by Pretargeting, Journal of Nuclear Medicine, vol.49, issue.1, pp.158-163, 2007. ,
Stably tethered multifunctional structures of defined composition made by the dock and lock method for use in cancer targeting, Proceedings of the National Academy of Sciences, vol.103, issue.18, pp.6841-6846, 2006. ,
Recombinant Bispecific Monoclonal Antibodies Prepared by the Dock-and-Lock Strategy for Pretargeted Radioimmunotherapy, Seminars in Nuclear Medicine, vol.40, issue.3, pp.190-203, 2010. ,
Pretargeted 177Lu Radioimmunotherapy of Carcinoembryonic Antigen-Expressing Human Colonic Tumors in Mice, Journal of Nuclear Medicine, vol.51, issue.11, pp.1780-1787, 2010. ,
Predictive patient-specific dosimetry and individualized dosing of pretargeted radioimmunotherapy in patients with advanced colorectal cancer, European Journal of Nuclear Medicine and Molecular Imaging, vol.41, issue.8, pp.1593-602, 2014. ,
Pharmacokinetics and Dosimetry Studies for Optimization of Pretargeted Radioimmunotherapy in CEA-Expressing Advanced Lung Cancer Patients, Frontiers in Medicine, vol.2, issue.6, p.84, 2015. ,
URL : https://hal.archives-ouvertes.fr/hal-01258870
A method for accurate modelling of the crystal response function at a crystal sub-level applied to PET reconstruction, Physics in Medicine and Biology, vol.56, issue.3, pp.793-809, 2011. ,
Recent Advances and Future Advances in Time-of-Flight PET, Nucl Instrum Methods Phys Res A, vol.580, issue.2, pp.919-943, 2010. ,
Recent developments in PET detector technology, Physics in Medicine and Biology, vol.53, issue.17, pp.R287-R317, 2008. ,
Advances in Immuno?Positron Emission Tomography: Antibodies for Molecular Imaging in Oncology, Journal of Clinical Oncology, vol.30, issue.31, pp.3884-3892, 2012. ,
Immuno-PET of Cancer: A Revival of Antibody Imaging, Journal of Nuclear Medicine, vol.52, issue.8, pp.1171-1172, 2011. ,
Immuno?PET: A Navigator in Monoclonal Antibody Development and Applications, The Oncologist, vol.12, issue.12, pp.1379-1389, 2007. ,
ImmunoSPECT and ImmunoPET of IGF-1R Expression with the Radiolabeled Antibody R1507 in a Triple-Negative Breast Cancer Model, Journal of Nuclear Medicine, vol.51, issue.10, pp.1565-1572, 2010. ,
Molecular Imaging of HER2-Expressing Malignant Tumors in Breast Cancer Patients Using Synthetic 111In- or 68Ga-Labeled Affibody Molecules, Journal of Nuclear Medicine, vol.51, issue.6, pp.892-897, 2010. ,
A Novel Method of 18F Radiolabeling for PET, Journal of Nuclear Medicine, vol.50, issue.6, pp.991-998, 2009. ,
Bispecific antibody pretargeting PET (immunoPET) with an 124I-labeled hapten-peptide, J Nucl Med, vol.47, issue.10, pp.1678-88, 2006. ,
Pretargeted Immuno?Positron Emission Tomography Imaging of Carcinoembryonic Antigen?Expressing Tumors with a Bispecific Antibody and a68Ga- and18F-Labeled Hapten Peptide in Mice with Human Tumor Xenografts, Molecular Cancer Therapeutics, vol.9, issue.4, pp.1019-1027, 2010. ,
Performance of Immuno-Positron Emission Tomography with Zirconium-89-Labeled Chimeric Monoclonal Antibody U36 in the Detection of Lymph Node Metastases in Head and Neck Cancer Patients, Clinical Cancer Research, vol.12, issue.7, pp.2133-2140, 2006. ,
Quantitative PET imaging of Met-expressing human cancer xenografts with 89Zr-labelled monoclonal antibody DN30, European Journal of Nuclear Medicine and Molecular Imaging, vol.35, issue.10, pp.1857-1867, 2008. ,
Positron Emission Tomography/Computed Tomography Identification of Clear Cell Renal Cell Carcinoma: Results From the REDECT Trial, Journal of Clinical Oncology, vol.31, issue.2, pp.187-194, 2013. ,
Preoperative characterisation of clear-cell renal carcinoma using iodine-124-labelled antibody chimeric G250 (124I-cG250) and PET in patients with renal masses: a phase I trial, The Lancet Oncology, vol.8, issue.4, pp.304-310, 2007. ,
Correlation of In Vivo and In Vitro Measures of Carbonic Anhydrase IX Antigen Expression in Renal Masses Using Antibody 124I-cG250, Journal of Nuclear Medicine, vol.52, issue.4, pp.535-540, 2011. ,
Syndecan-1 antigen, a promising new target for triple-negative breast cancer immuno-PET and radioimmunotherapy. A preclinical study on MDA-MB-468 xenograft tumors, EJNMMI Research, vol.1, issue.1, p.20, 2011. ,
URL : https://hal.archives-ouvertes.fr/inserm-00626326
,
Biodistribution of 89Zr-trastuzumab and PET Imaging of HER2-Positive Lesions in Patients With Metastatic Breast Cancer, Clinical Pharmacology & Therapeutics, vol.87, issue.5, pp.586-592, 2010. ,
Improving the evaluation of new cancer treatments: challenges and opportunities, Nature Reviews Cancer, vol.3, issue.4, pp.303-309, 2003. ,
,
124I-huA33 Antibody PET of Colorectal Cancer, Journal of Nuclear Medicine, vol.52, issue.8, pp.1173-1180, 2011. ,
High-quality 124I-labelled monoclonal antibodies for use as PET scouting agents prior to 131I-radioimmunotherapy, European Journal of Nuclear Medicine and Molecular Imaging, vol.31, issue.12, pp.1645-1652, 2004. ,
Preparation and evaluation of 89Zr-Zevalin for monitoring of 90Y-Zevalin biodistribution with positron emission tomography, European Journal of Nuclear Medicine and Molecular Imaging, vol.33, issue.11, pp.1337-1345, 2006. ,
Potential of Immuno-Positron Emission Tomography for Tumor Imaging and Immunotherapy Planning, Clinical Cancer Research, vol.12, issue.7, pp.1958-1960, 2006. ,
VEGF-PET Imaging Is a Noninvasive Biomarker Showing Differential Changes in the Tumor during Sunitinib Treatment, Cancer Research, vol.71, issue.1, pp.143-153, 2010. ,
Multi-observation PET image analysis for patient follow-up quantitation and therapy assessment, Physics in Medicine and Biology, vol.56, issue.18, pp.5771-5788, 2011. ,
URL : https://hal.archives-ouvertes.fr/inserm-00707280